Mhao, NS and Al-Hilli, AS and Hadi, NR and Jamil, DA and Al-Aubaidy, HA, A comparative study to illustrate the benefits of using ethinyl estradiol-cyproterone acetate over metformin in patients with polycystic ovarian syndrome, Diabetes & metabolic syndrome, 10, (1) pp. S95-S98. ISSN 1871-4021 (2016) [Refereed Article]
Copyright 2015 Diabetes India
Aim: This study was done to illustrate the clinical and biochemical effects of ethinyl estradiol-cyproterone acetate (EE-AC) and metformin in this disease.
Methods: This was a randomized control trial study, done on twenty-six female patients already diagnosed as cases of PCOS. Participants were divided into two study groups: group one (Group 1), received metformin of 500mg twice daily and the second group (Group 2), was given ethinyl estradiol-cyproterone acetate for 21 consecutive days followed by 7 days drug-free. The course of the treatment for both groups was continued for three consecutive months.
Results: Group 1 showed a statistical significant increase in serum high density lipoprotein cholesterol (HDL-C) levels (P = 0.006) and a decrease in the level of triglyceride (TG) (P = 0.006). In addition, Group 1 had a significant reduction in the levels of very density lipoprotein cholesterol (VLDL-C) (P = 0.006). Group 2 had a significant increase in serum TG levels (P = 0.01), associated with a significant decrease in serum LDL-C (P = 0.04). Serum testosterone was significantly reduced in group 1 (P = 0.038). This was associated with an improvement in glucose tolerance test (GTT) and BMI in the same group (group 1). Group 2, had an improvement in the menstrual cycle control; hirsutism and acne.
Conclusion: This study showed that metformin treatment is beneficial in improving serum lipids; glucose homeostasis and BMI, however, the ethinyl estradiol-cyproterone acetate is superior in improving the clinical manifestation of patients with PCOS, including menstrual cycle regulation, hyperandrogenic state.
|Item Type:||Refereed Article|
|Keywords:||ethinyl estradiol-cyproterone acetate, metabolic regulation, metformin, polycystic ovarian syndrome|
|Research Division:||Medical and Health Sciences|
|Research Group:||Medical Biochemistry and Metabolomics|
|Research Field:||Medical Biochemistry and Metabolomics not elsewhere classified|
|Objective Group:||Clinical Health (Organs, Diseases and Abnormal Conditions)|
|Objective Field:||Endocrine Organs and Diseases (excl. Diabetes)|
|Author:||Jamil, DA (Dr Dina Jamil)|
|Author:||Al-Aubaidy, HA (Dr Hayder Al-Aubaidy)|
|Deposited By:||Medicine (Discipline)|
Repository Staff Only: item control page